Tests an antidepressant with or without memantine in adults with depression

Trial details

Who runs it

Jeffrey Miller

Trial code

NCT07139834

Record updated

15 September 2026

Original description

This study seeks to examine the effects of treatment with a selective serotonin reuptake inhibitor (SSRI), escitalopram, a first-line treatment for depression, in combination with placebo or with extended-release memantine, on neuropsychological function, regional brain activity assessed by functional magnetic resonance imaging, and depressive symptoms, in participants with Major Depressive Disorder. Escitalopram is administered in an open-label fashion in this study; extended release memantine is administered in a double-blind, randomized, placebo-controlled manner.Read full original descriptionShow less

Examining the Effects of Escitalopram and Memantine on Pattern Separation in Major Depressive Disorder

This study seeks to examine the effects of treatment with a selective serotonin reuptake inhibitor (SSRI), escitalopram, a first-line treatment for depression, in combination with placebo or with extended-release memantine, on neuropsychological function, regional brain activity assessed by functional magnetic resonance imaging, and depressive symptoms, in participants with Major Depressive Disorder. Escitalopram is administered in an open-label fashion in this study; extended release memantine is administered in a double-blind, randomized, placebo-controlled manner.

Inclusion: Age 18-50; Current diagnosis of MDD without psychotic features assessed within three weeks of study enrollment; 17-item Hamilton Depression Rating Scale score ≥17 assessed within 3 weeks of study enrollment; Using an effective form of contraception at study enrollment and agrees to continue throughout study participation for individuals of child-bearing potential; Capacity to provide informed consent; Proficient in English; Willing to provide emergency contact.

Exclusion: Currently taking an antidepressant medication at study enrollment; Current or recent (past 6 months) treatment with antipsychotics; current or recent (past 1 month) treatment with benzodiazepines; current use of prescribed stimulant medication; current use of other NMDA antagonists (amantadine, ketamine, dextromethorphan); Concurrent or recent (past 6 months) participation in another clinical trial for mental illness involving an investigational product or device; Lack of response to or intolerable side-effects from trials of two or more selective serotonin reuptake inhibitors of adequate dose and duration at study enrollment; Electroconvulsive therapy (ECT) in the past 6 months; Evidence of current unstable medical illness, including liver or renal impairment, or unstable cardiovascular or respiratory illness; Current genitourinary conditions that raise urine pH such as a) renal tubular acidosis or b) severe infection of the urinary tract; Clinically significant neurological conditions, including a) history of stroke, b) previous head injury with evidence of cognitive impairment, c) history of malignancy or d) history of seizure disorder. (headache, migraines, pain disorders, and other conditions not exclusionary); Lifetime diagnosis of a) bipolar disorder, b) psychotic disorder, or c) dementia; Current substance use disorder other than tobacco use disorder; History of hypersensitivity or allergic reaction to a) memantine hydrochloride or any of its components/excipients, b) citalopram, escitalopram, or any other component of the product, or c) sertraline or any other component of the product; Any condition or material in the body that is a contraindication for MRI procedures; QTc interval greater than 500 ms; Pregnant or breastfeeding at time of enrollment; Current active suicidal ideation; Current use of disulfiram with oral concentrate, MAOIs (including linezolid or IV methylene blue), or pimozide; Weight that exceeds 300 lbs or inability to fit into MRI scanner; MST LDI score greater than 0.5.

ClinicalTrials.gov NCT07139834